

# Dariush Etemadmoghadam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6608726/publications.pdf>

Version: 2024-02-01

9  
papers

2,311  
citations

1040056

9  
h-index

1474206

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

4726  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. <i>Journal of Pathology</i> , 2021, 253, 41-54.	4.5	54
2	Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. <i>Clinical Cancer Research</i> , 2019, 25, 3962-3973.	7.0	36
3	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 569-580.	7.0	79
4	Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature</i> , 2015, 521, 489-494.	27.8	1,206
5	Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver. <i>Clinical Cancer Research</i> , 2014, 20, 6618-6630.	7.0	96
6	AKT1 gene amplification as a biomarker of treatment response in ovarian cancer: Mounting evidence of a therapeutic target. <i>Gynecologic Oncology</i> , 2014, 135, 409-410.	1.4	9
7	Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. <i>Molecular Oncology</i> , 2014, 8, 656-668.	4.6	117
8	Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5960-5971.	7.0	97
9	Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. <i>Journal of Pathology</i> , 2010, 221, 49-56.	4.5	617